You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory Mantle Cell Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

Not yet recruiting
  • Mantle-cell Lymphoma
  • Polatuzumab, bendamustin und rituximab
  • (no location specified)
May 11, 2023

Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

Not yet recruiting
  • Mantle Cell Lymphoma Refractory
  • (no location specified)
May 16, 2023

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Low Dose Radiation Therapy)

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Low Dose Radiation Therapy
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Lymphoma Trial in Beijing, Shanghai City, Seoul (Obinutuzumab, Glofitamab, Rituximab)

Recruiting
  • Lymphoma
  • Beijing, China
  • +2 more
Oct 12, 2023

Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma Trial (BGB-11417)

Not yet recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • (no location specified)
Jul 25, 2022

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma Trial in India (Acalabrutinib capsule)

Active, not recruiting
  • Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
  • Acalabrutinib capsule
  • Ahmedabad, India
  • +12 more
Feb 2, 2023

Recurrent Refractory Mantle Cell Lymphoma

Recruiting
  • Mantle Cell Lymphoma
    • Beijing, Beijing, China
      Peking University Third Hospital
    Aug 1, 2022

    Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)

    Recruiting
    • Recurrent Mantle Cell Lymphoma
    • Refractory Mantle Cell Lymphoma
    • Biospecimen Collection
    • Follow-Up
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte, New Haven (Copanlisib Hydrochloride,

    Recruiting
    • Recurrent Mantle Cell Lymphoma
    • Refractory Mantle Cell Lymphoma
    • Duarte, California
    • +1 more
    Aug 3, 2022

    Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Rochester (procedure, drug, biological)

    Not yet recruiting
    • Recurrent Mantle Cell Lymphoma
    • Refractory Mantle Cell Lymphoma
    • Biopsy
    • +10 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jun 9, 2023

    Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)

    Not yet recruiting
    • Lymphoma, Mantle-Cell
    • +7 more
    • (no location specified)
    Jun 21, 2022

    Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)

    Not yet recruiting
    • Mantle Cell Lymphoma
    • Duarte, California
      City of Hope Medical Center
    Sep 20, 2023

    Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II

    Active, not recruiting
    • Phase I: Relapsed or Refractory B-cell Malignancies
    • +2 more
    • Beijing, China
    • +22 more
    Dec 8, 2022

    Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,

    Recruiting
    • Recurrent Mantle Cell Lymphoma
    • Refractory Mantle Cell Lymphoma
    • Acalabrutinib
    • CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    • Duarte, California
      City of Hope Comprehensive Cancer Center
    Jun 16, 2022

    Mantle Cell Lymphoma, MCL Trial in United States (Tafasitamab, Lenalidomide)

    Recruiting
    • Mantle Cell Lymphoma
    • MCL
    • Basking Ridge, New Jersey
    • +6 more
    Mar 27, 2023

    Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Eprenetapopt, Venetoclax)

    Withdrawn
    • Recurrent Mantle Cell Lymphoma
    • Refractory Mantle Cell Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 23, 2022

    Mantle-Cell Lymphoma Trial in United States (Ixazomib, Ibrutinib)

    Active, not recruiting
    • Mantle-Cell Lymphoma
    • Atlanta, Georgia
    • +13 more
    Nov 17, 2022

    Mantle Cell Lymphoma Trial in Hackensack (Lenalidomide, Ibrutinib, Rituximab)

    Active, not recruiting
    • Mantle Cell Lymphoma
    • Hackensack, New Jersey
      The Cancer Center at Hackensack University Medical Center
    May 3, 2022

    Relapsed/Refractory Mantle Cell Lymphoma Trial in Worldwide (brexucabtagene autoleucel, Cyclophosphamide, Fludarabine)

    Active, not recruiting
    Has Results
    • Relapsed/Refractory Mantle Cell Lymphoma
    • brexucabtagene autoleucel
    • +3 more
    • Gilbert, Arizona
    • +31 more
    Jan 26, 2023

    Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell Trial in United States (ABT-199 and Ibrutinib Combination)

    Completed
    • Lymphoma, Mantle-Cell
    • Recurrent Lymphoma, Mantle-Cell
    • ABT-199 and Ibrutinib Combination
    • Duarte, California
    • +3 more
    May 22, 2022

    Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Seattle

    Not yet recruiting
    • Post-Transplant Lymphoproliferative Disorder
    • +10 more
    • Loncastuximab Tesirine
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jul 6, 2022

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

    Recruiting
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +13 more
    • Polatuzumab Vedotin
    • +3 more
    • Scottsdale, Arizona
    • +11 more
    Aug 23, 2022

    CNS Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Houston (Akt/ERK Inhibitor ONC201,

    Terminated
    Has Results
    • Central Nervous System Lymphoma
    • +6 more
    • Akt/ERK Inhibitor ONC201
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Mar 30, 2022

    CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

    Active, not recruiting
    • CCND1 Positive
    • +6 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 11, 2022